Table 1 Distribution of Demographic and Clinical Findings of the Patients

Gender, n (%)

1.000

Female

38 (25.7)

24 (25.5)

14 (25.9)

Male

110 (74.3)

70 (74.5)

40 (74.1)

Age, year, median (min-max)

65 (21–91)

61 (21–89)

70.5 (40–91)

< 0.001

APACHE II score (when colistin therapy is started) (min-max)

17 (2–49)

16 (2–43)

20.5 (5–49)

0.004

ICU admission diagnosis n (%)

Pneumonia

135 (91.2)

86 (91.5)

49 (90.7)

1.000

Bloodstream infection

11 (7.4)

6 (6.4)

5 (9.3)

0.530

Urinary tract infection

6 (4.1)

5 (5.3)

1 (1.9)

0.416

Soft tissue infection

4 (2.7)

1 (1.1)

3 (5.6)

0.138

ICU admission CCI score, median (min-max)

3 (0–10)

3 (0–10)

4 (0–9)

0.002

Comorbidity, n (%)

123 (83.1)

75 (79.8)

48 (88.9)

0.232

HT

37 (25)

21 (22.3)

16 (29.6)

0.430

DM

29 (19.6)

19 (20.2)

10 (18.5)

0.972

CHF

31 (20.9)

15 (16)

16 (29.6)

0.079

COPD

24 (16.2)

18 (19.1)

6 (11.1)

0.296

CVD

21 (14.2)

11 (11.7)

10 (18.5)

0.368

Malignancy

31 (20.9)

19 (20.2)

12 (22.2)

0.937

CAD

36 (24.3)

20 (21.3)

16 (29.6)

0.347

ICU LOS, days, median (min-max)

32 (3–178)

32 (3–178)

32 (4–128)

0.484

Hospital LOS, days, median (min-max)

41 (10–214)

46 (11–214)

39.5 (10–198)

0.873

From onset of colistin to AKI development time, days, median (min-max)

6 (1–29)

NA

6 (1–29)

NA

Duration of colistin treatment, days, median (min-max)

12 (3–36)

11.5 (3–30)

13.5 (3–36)

0.045

Duration of colistin treatment > 14 days, n (%)

52 (35.1)

29 (30.9)

23 (42.6)

0.207

Basal creatinine level, mg/dl, median (min-max)

0.6 (0.2–1.2)

0.6 (0.2–1.1)

0.7 (0.2–1.2)

0.027

KDIGO, n (%)

NA

Stage-I

10 (18.5)

NA

10 (18.5)

Stage-II

15 (27.8)

NA

15 (27.8)

Stage-III

29 (53.7)

NA

29 (53.7)

Haemodialysis, n (%)

IHD

7 (4.7)

NA

6 (4)

CRRT

Vasopressor use, n (%)

60 (40.5)

28 (29.8)

32 (59.3)

< 0.001

Mortality, n (%)

58 (39.2)

28 (29.8)

30 (55.6)

0.004